- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00102531
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
July 5, 2017 updated by: Insmed Incorporated
Phase Ib/IIa Study of SLIT Cisplatin by Inhalation in the Treatment of Patients Wtih Relapsed/Progressive Osteosarcoma Metastatic to the Lung
Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10467
- The Albert Einstein College of Medicine Montefiore Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years to 50 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically proven, Progressive or recurrent high grade osteosarcoma metastatic to the lung
- Patients with histologically proven, fully malignant high-grade osteosarcoma of bone
- Measureable pulmonary metastases
- Less than grade 3 neuropathies, insignificant decreases in cardiac or auditory function
- ECOG performance status of 0, 1 or 2
- FEV1 of 50% or greater of predicted value
- FEV1/FVC ratio of 65% or greater
- Serum creatinine of ≤ 1.5 mg/dl
- Total bilirubin ≤ 1.5mg/dl and SGOT or SGPT < 2.5 times upper normal limit
- ANC of ≥ 1,000/mm3 and platelet count of ≥ 100,000/mm3
Exclusion Criteria:
- Grade 3 or higher painful neuropathy persisting after a prior platinum containing regimen
- Patients who are pregnant or are of childbearing potential and not using methods to avoid pregnancy
- Concurrent systemic chemotherapy
- Greater than Grade 2 pulmonary toxicity
- Pulmonary atelectasis
- Reactive airway disease which has resulted in hospitalization within the last year or which requires daily treatment with bronchodilator therapy
- Concurrent serious infections
- Unstable or serious concurrent medical condition
- Recent major surgery or thoracic radiation therapy or chemotherapy
- Significant pulmonary fibrosis secondary to prior radiation
- Major ventilatory distribution abnormalities
- Osteosarcoma secondary to radiation or premalignant conditions
- History of prior malignancy
- Low grade osteosarcoma, parosteal or periosteal sarcoma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cisplatin liposomal 24 mg/m2
Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles.
|
Other Names:
|
Experimental: Cisplatin liposomal 36 mg/m2
The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Study Medication Was to be Considered Effective if the Population Response Rate Was Found to be Greater Than 20% and Individuals Who Demonstrated a CR or PR or Whose Tumours Demonstrated a Grade 3 or 4 Histologic Response at the Time of Surgery.
Time Frame: 4 to 48 weeks
|
4 to 48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Renu Gupta, MD, Transave Inc.
- Principal Investigator: Richard Gorlick, MD, The Albert Einstein College of Medicine Montefiore Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 12, 2005
Primary Completion (Actual)
March 1, 2008
Study Completion (Actual)
March 17, 2008
Study Registration Dates
First Submitted
January 29, 2005
First Submitted That Met QC Criteria
January 28, 2005
First Posted (Estimate)
January 31, 2005
Study Record Updates
Last Update Posted (Actual)
August 1, 2017
Last Update Submitted That Met QC Criteria
July 5, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TR02-2421
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteosarcoma Metastatic
-
Children's Oncology GroupNational Cancer Institute (NCI)Not yet recruitingMetastatic Osteosarcoma | Localized Osteosarcoma | Unresectable Osteosarcoma | Resectable Osteosarcoma
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Ewing Sarcoma | Recurrent Osteosarcoma | Stage III Osteosarcoma AJCC v7 | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Metastatic Ewing Sarcoma | Unresectable Ewing Sarcoma | Unresectable OsteosarcomaFrance
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized Osteosarcoma | Osteoblastic OsteosarcomaUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Unresectable Osteosarcoma | Locally Advanced OsteosarcomaUnited States
-
National Cancer Institute (NCI)SuspendedMetastatic Osteosarcoma | Localized Osteosarcoma | High Grade Osteosarcoma | Secondary OsteosarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated LiposarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic OsteosarcomaUnited States, Canada, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI); University College, London; Medical Research...CompletedMetastatic Osteosarcoma | Localized OsteosarcomaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Clinical Trials on Cisplatin liposomal
-
NYU Langone HealthNational Cancer Institute (NCI)Completed
-
Allarity TherapeuticsCompletedPhase 1: Advanced or Refractory Solid Tumours | Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin CancerDenmark
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerUnited States
-
Moleculin Biotech, Inc.Active, not recruitingSarcoma,Soft Tissue | Pulmonary MetastasisUnited States
-
M.D. Anderson Cancer CenterCompletedAdvanced CancerUnited States
-
Clemens TempferCompleted
-
Ruhr University of BochumCompleted
-
The First Affiliated Hospital with Nanjing Medical...Innovent Biologics (Suzhou) Co. Ltd.Active, not recruitingEsophageal Squamous Cell CarcinomaChina
-
European Organisation for Research and Treatment...Medical Research CouncilCompletedSarcomaFrance, Saudi Arabia, Denmark, Belgium, Netherlands, Portugal, Slovenia, United Kingdom
-
Centre Hospitalier Universitaire VaudoisTerminatedPleural Effusion, MalignantSwitzerland